Alpha Tau Medical Ltd. (NASDAQ: DRTS)

Alpha Tau Medical Ltd., known by its stock symbol DRTS, is a company that operates in the oncology therapeutics industry. This clinical-stage company is dedicated to developing and commercializing its proprietary Alpha DaRT technology, which harnesses the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors.

Alpha Tau Medical's primary business activity is the development of its Alpha DaRT technology for the treatment of a wide range of tumors. These include superficial lesions, internal organs, and metastatic diseases. The technology has shown promising results in clinical trials, with a 100% overall response rate and over 78% complete response rate in a first-in-human study of locally advanced and recurrent squamous cell carcinoma.

The Alpha DaRT technology has been evaluated in clinical trials for the treatment of superficial lesions, including skin, head, and neck cancers. The technology has shown promising results in these trials, with a 100% complete response rate in a multi-center pilot feasibility trial in ten patients with malignant skin or superficial soft tissue tumors. Additionally, the company is conducting clinical trials to evaluate the feasibility and safety of the Alpha DaRT technology for the treatment of internal organs, including the pancreas, prostate, brain, breast, lung, and liver. The technology has shown promising results in pre-clinical studies, with a high relative biological efficiency and a well-defined range of travel. Furthermore, the company is investigating the potential of the Alpha DaRT technology to treat metastatic disease, by combining the technology with systemic therapies, such as checkpoint inhibitors.

Alpha Tau Medical has a strong competitive position in the industry due to its proprietary Alpha DaRT technology. This technology has several competitive advantages, including its high relative biological efficiency, well-defined range of travel, and potential to destroy solid tumors while preserving healthy tissue. The technology is designed to be easy to use, with a quick and minimally invasive procedure that can be performed on an outpatient basis.

The company's market opportunity is significant, with the global cancer therapeutics market expected to reach $143.6 billion by 2025, growing at a compound annual growth rate of 7.4% from 2020 to 2025. The market for alpha radiation therapy is a small but growing segment of this market, with a potential to reach $1.5 billion by 2025.